This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary goal of this study will look at patients with psoriasis to see whether infliximab is safe and tolerable at infusion doses of 3 mg/kg or 5 mg/kg compared to receiving placebo. The study will also look at measures of quality of life, side effects, changes in routine labs, and change in psoriasis.
Showing the most recent 10 out of 675 publications